• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Trial shows drug can dramatically reduce weight of people with obesity

Bioengineer by Bioengineer
October 23, 2017
in Biology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.

On average, people lost 5kg (11lbs) over a 12 week period after receiving weekly doses of semaglutide, a compound currently being developed as a treatment for Diabetes.

Most of the weight loss came from a reduction in body fat, researchers at the University of Leeds found after reviewing its effectiveness. The drug reduced food cravings, with people choosing to eat smaller meals and decreasing their preferences for foods with a higher fat content. The study also added to the scientific understanding of how drug therapy can be used to tackle obesity. For the first time, scientists saw the benefit of very specific targeting of receptors or sensors that could affect multiple components of the brain's appetite control system.

John Blundell, Professor of Psycho-Biology at the University of Leeds and lead researcher, said: "What was striking was the potency of the drug's action. We saw results in 12 weeks which may take as long as six months with other anti-obesity medication.

"The drug reduced hunger but also cravings for food and the sensation of wanting to eat – and these had previously been thought to stem from different parts of the brain."

The research has been published in the journal Diabetes, Obesity and Metabolism.

Semaglutide is a new drug being developed by the Danish pharmaceutical company Novo Nordisk as a treatment for diabetes.

Its chemical structure is very similar to the naturally-occurring hormone GLP-1 which is believed to act on the appetite control centre in the hypothalamus in the brain to reduce feelings of hunger.

Given the close similarity between semaglutide and the body's own appetite-control chemical, the study set out to examine whether the drug could also be used to tackle obesity by acting on the brain's appetite control receptors.

Professor Blundell said: "The potency of the drug is probably due to the action of the GLP-1 protein receptors on broad aspects of the appetite control system including hunger, craving and rewarding aspects of food."

In the study, the drug was given to 28 people with a body mass index (BMI) range of 30 to 45 kg/m2 – meaning they were very overweight with a lot of body fat.

The participants were split in two groups – half got semaglutide and the other half a placebo (dummy) substance for 12 weeks. They did not know what they were getting.

At the end of the 12 weeks, they were invited into a testing centre and offered a lunch and evening meal and told to consume as much as they needed to feel 'pleasantly full'. What they were eating was recorded, along with food preferences and their sensations of liking and wanting food. Body weight and body composition – the percentage of body fat – were also recorded.

They then repeated the process, with participants who got semaglutide this time getting the placebo and vice versa.

The results were then compared. The research team found that on average the daily energy intake, a measure of the amount of food consumed, was 24 per cent lower with semaglutide.

A further feature of the study was that measured energy expenditure from metabolic processes (the Resting Metabolic Rate) remained roughly the same throughout the experiment suggesting the weight loss could not be due to metabolism becoming more active. Consequently the fat loss produced by the drug could be attributed to better control over appetite.

Professor Blundell added: "A drug that reduces daily food intake by about a quarter with a substantial reduction in body fat will help some people to feel more in control of their lives and will help to prevent the onset of poor health that often arises from obesity" Semaglutide is in the advanced stages of development but is not yet on the market.

The study was funded by Novo Nordisk but carried out independently. The University of Leeds was asked to conduct the research because of its expertise in the science and investigation of appetite control.

###

Notes to editors

more information, please contact David Lewis in the University of Leeds press office on 0113 343 8059 or [email protected]

The paper is available here.

DOI: 10.1111/dom.12932

University of Leeds

The University of Leeds is one of the largest higher education institutions in the UK, with more than 33,000 students from more than 150 different countries, and a member of the Russell Group of research-intensive universities.

We are a top ten university for research and impact power in the UK, according to the 2014 Research Excellence Framework, and are in the top 100 for academic reputation in the QS World University Rankings 2018. Additionally, the University was awarded a Gold rating by the Government's Teaching Excellence Framework in 2017, recognising its 'consistently outstanding' teaching and learning provision. Twenty-four of our academics have been awarded National Teaching Fellowships – more than any other institution in England, Northern Ireland and Wales – reflecting the excellence of our teaching. http://www.leeds.ac.uk

Follow University of Leeds or tag us in to coverage

Twitter

Facebook

LinkedIn

Instagram

Media Contact

David Lewis
[email protected]
44-011-334-38059
@universityleeds

http://www.leeds.ac.uk

http://dx.doi.org/10.1111/dom.12932

Share12Tweet7Share2ShareShareShare1

Related Posts

Yeast Proteins Unlock the Mysteries of Drought Resistance

Yeast Proteins Unlock the Mysteries of Drought Resistance

October 6, 2025
Hub1 Overexpression: Revolutionizing Transcription and Splicing in Yeast

Hub1 Overexpression: Revolutionizing Transcription and Splicing in Yeast

October 6, 2025

Scientists Secure $3.7 Million Grant to Explore the Link Between Perimenopause and Psychosis

October 6, 2025

Streamlined Batch Processing of Biomedical Regression Models in R Made Easy

October 6, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    95 shares
    Share 38 Tweet 24
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    93 shares
    Share 37 Tweet 23
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    73 shares
    Share 29 Tweet 18
  • New Insights Suggest ALS May Be an Autoimmune Disease

    71 shares
    Share 28 Tweet 18

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

PRDM6: A Key Protector Against PCOS

Bright Red-NIR Glow from Carbodicarbene Borenium Ions

Co-Digestion Boosts Biomethane from Jatropha, Poultry, Food Waste

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.